Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.48 |
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772298 | 0.95 | HTR6 (0.46) | HTR6BRD4HTR1ADRD2HTR2A | |
| SCHEMBL1773025 | 0.82 | HTR6 (0.45) | HTR6BRD4 | |
| SCHEMBL1772003 | 0.81 | BRD4 (0.55) | HTR6BRD4HTR1ADRD2HTR2A | |
| SCHEMBL1773389 | 0.80 | HTR6 (0.51) | HTR6BRD4HTR1ADRD2HTR2A | |
| SCHEMBL1773252 | 0.80 | BRD4 (0.58) | HTR6BRD4HTR1ADRD2HTR2A | |
| SCHEMBL1772886 | 0.80 | HTR6 (0.55) | HTR6DRD2 | |
| SCHEMBL1772309 | 0.78 | HTR6 (0.43) | HTR6BRD4 | |
| SCHEMBL1773806 | 0.76 | HTR6 (0.53) | HTR6DRD2 | |
| SCHEMBL1772299 | 0.75 | HTR6 (0.42) | HTR6BRD4HTR1ADRD2HTR2A | |
| SCHEMBL13613784 | 0.74 | KMT2A (0.59) | HTR6BRD4DRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HTR6 4804/4885BRD4 3329/4885HTR1A 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.